Agoracom Blog Home

Archive for the ‘Tetra Bio-Pharma Inc.’ Category

Tetra Bio-Pharma Signs Definitive Agreement for Two Products with Panag Pharma $TBP.ca

Posted by AGORACOM-JC at 4:31 PM on Tuesday, May 23rd, 2017

Tbp large

  • Signed definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation
  • Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion

OTTAWA, ONTARIO–(May 23, 2017) - Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion. The recent press release on May 17th for the filing of a patent in ocular disease combined with the patents from Panag in the ocular space make this agreement very lucrative.

Per the definitive agreement, Tetra will have exclusive access to sell the ocular and topical drug products in North America with right of first negotiation for outside U.S. and Canadian territories. In addition, Tetra will have a right of first negotiation for future cannabinoid-based products.

Tetra will work in close collaboration with Panag’s team of experts to ensure a rapid and successful development leading to marketing authorization. Panag will continue work in the development of novel products for unmet medical need and Tetra will take the lead in commercializing these novel drug products.

“We are very pleased to announce this partnership with Panag as we work towards building an innovative product pipeline focused on cannabis,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Tetra is committed to generating revenues in 2017 by launching several products in the retail market through its partnership with Panag.”

Panag has developed potential new cannabinoid-based therapies for ocular and topical anti-inflammatory and pain markets. The total ocular anti-inflammatory market was estimated at over $3 billion in the USA in 2014 and includes conditions such as post-op inflammation, allergic conjunctivitis and inflammatory dry eye. Panag also developed a cannabinoid topical drug product for the local treatment of pain and inflammation. In 2014, the over the counter sales of topical analgesics were estimated at over $2.5 billion according to IMS.

“We will prioritize the development of the ocular therapy as this is a promising innovative product with high medical need and a significant potential financial reward,” said Guy Chamberland, Chief Scientific Officer of Tetra Bio-Pharma. Tetra has positioned itself to become a leader in topical pain relief.

Corporate Update:

Tetra changed today at the opening of the U.S. markets its OTCQB stock symbol to TBPMF.

The Company issued 501,800 new shares as part as of a service agreement as previously announced in a news release on June 20, 2016.

The Company issued an additional 250,000 new shares as part of a service agreement with MAPH Enterprises, LLC, effective May 8, 2017 to broaden U.S. investor awareness.

About Panag Pharma:

Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safenon-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in the area of pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new approach to the treatment of chronic pain and inflammation.

About Tetra Bio-Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Source: Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com
www.tetrabiopharma.com

Tetra Bio-Pharma Files Patent for the Treatment of Cancer and Ocular Disease $TBP.ca

Posted by AGORACOM-JC at 4:17 PM on Wednesday, May 17th, 2017

Tbp large

  • Submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease
  • Global market for cancer drugs has hit US$100 billion in annual sales
  • Could reach US$147 billion by 2018, according to a new report by IMS Institute for Healthcare Informatics

OTTAWA, ONTARIO–(May 17, 2017) - Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:GRPOF), today announced that Tetra has submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease.

The global market for cancer drugs has hit US$100 billion in annual sales, and could reach US$147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics. According to Transparency Market Research, the global ophthalmic drug market is expected to reach US$21.6 billion by 2018 due to high incidence of eye-related disorders amongst geriatrics. The provisional patent aims to protect new pharmaceutical combinations of cannabinoids and terpenoids to inhibit a specific signaling pathway, known as Hedgehog (Hh), and their use to combat human diseases.

“Filing of this provisional patent marks the launch of an innovative and exciting project that could not only impact patients suffering from a variety of human diseases, but also further Tetra’s interests in developing and commercializing novel cannabinoid-based pharmaceutical drugs,” said Dr. Guy Chamberland, Chief Scientific Officer of Tetra. “The rationale forming the basis for this project is well founded and our research team has extensive scientific experience in the Hh field. We look forward to quickly advancing the project through key academic collaborations, with the ultimate goal of developing multiple pharmaceutical treatments.”

Background Information:

Hh signaling is a critical developmental molecular signaling pathway and inappropriate over activation of Hh is causal in several types of human tumors, including medulloblastoma, basal cell carcinoma, rhabdomyosarcoma, and multiple forms of leukemia, as well as liver, stomach, small cell lung, prostate, and breast cancers. Hh signaling also regulates the formation and remodeling of blood vessels, and aberrant blood vessel growth is implicated in several human diseases. The eye is particularly vulnerable to dysfunctional angiogenesis and neovascularization, such as in the case of diabetic retinopathy, age-related macular degeneration, neovascular glaucoma, retinal vein occlusion and retinopathy of prematurity, where inappropriate ocular blood vessel growth often leads to irreversible blindness if left untreated.

Currently, there are few clinically approved treatments for Hh-pathway-dependent cancers and drug resistance remains a major hurdle. As well, current treatment approaches to neovascular and angiogenic ocular disease are insufficiently effective and have significant adverse effects. Thus, there is a large need to develop novel therapies to treat human cancers and ocular disease related to blood vessel growth. Recently, cannabinoids have emerged as novel and potent inhibitors of the Hh signaling pathway and terpenoids have been shown to modulate the effects of cannabinoids through an undefined mechanism. Tetra looks to capitalize on these recent findings by filing a provisional patent for the use of cannabinoids in combination with terpenoids to treat Hh related cancer growth and aberrant blood vessel growth in the eye. Securing a provisional patent and achieving the freedom to operate is an important first step in the realization of this project.

About Tetra-Bio Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

Tetra Bio-Pharma Strengthens Management Team $TBP.ca

Posted by AGORACOM-JC at 4:34 PM on Wednesday, May 10th, 2017

Tbp large

  • Appointment of Robert Bechard to the position of Vice President, Finance and Business Development
  • Brings more than 20 years’ experience in the biopharmaceutical industry having worked for two lifescience venture capital funds, a pharmaceutical R&D management firm, a drug delivery company, and as a consultant to the biotech industry

OTTAWA, ONTARIO–(May 10, 2017) - Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF), today announced that it has strengthened its management team with the appointment of Robert Bechard to the position of Vice President, Finance and Business Development, effective today, May 10, 2017.

Mr. Bechard brings more than 20 years’ experience in the biopharmaceutical industry having worked for two lifescience venture capital funds, a pharmaceutical R&D management firm, a drug delivery company, and as a consultant to the biotech industry. As Vice President of Finance and Business Development, Mr. Bechard will be responsible for leading the charge on business development as it relates to the pharmaceutical side of the business and managing the financial side of the company.

During his tenure at RBC Lifesciences Funds I&II, Mr. Bechard was a member of the Senior Management team that delivered top quartile returns in two separate funds. RBC Lifesciences. During his 12-year term as a venture capitalist Mr. Bechard, made numerous investments, sat on the boards of more than 25 life science companies and was actively involved in the negotiation of numerous strategic alliances, partnerships, and outright sales to both pharmaceutical and biotech companies. As a Board member he played an active role in the negotiation of numerous exits and was also actively involved in taking several companies public in Canada and the U.S. In his two operating roles, he was instrumental in contributing to the growth of two companies actively involved in developing pharmaceuticals. As a consultant to the biopharmaceutical industry Mr. Bechard provided start-up companies with assistance in the areas of fundraising, business development and corporate development.

“We are most pleased to welcome Bob to the team as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Mr. Bechard has built great relations over his career in the pharmaceutical industry which will open new opportunities to further expand our product pipeline through partnerships as we build Tetra into a global leader in pharmaceutical cannabis.”

About Tetra Bio Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE: TBP) (OTCQB: GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(343) 689-0714
edward@tetrabiopharma.com

Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis in the Maritime Provinces & Quebec $TBP.ca

Posted by AGORACOM-JC at 8:45 AM on Wednesday, April 19th, 2017

Tbp large

  • Announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec
  • Enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001

OTTAWA, ONTARIO–(April 19, 2017) - Tetra Bio-Pharma Inc. (“Tetra”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) and Aphria Inc. (“Aphria”) (TSX:APH) (OTCQB:APHQF), announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.

Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001. The formulation and packaging will be completed by Tetra, under its CDSA dealer’s licence, at its New Brunswick facility. Based on the success of the venture, Tetra and Aphria may expand into other provinces. The venture is preparing to initiate its commercial operations early summer 2017 with revenues commencing in Tetra’s third quarter of 2017 and Aphria’s first quarter of 2018.

“This commercial venture is an important decision for Tetra shareholders as it will start generating revenues this summer which will be invested back into developing PPP001 as a prescription pharmaceutical,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra will be accelerating its manufacturing and quality studies as required by the U.S. and Canadian prescription drug and controlled substance regulations. The investment in this research will be offset by sales revenues generated under the ACMPR.”

“The commercial venture between Tetra and Aphria will enhance Aphria’s brand visibility and distribution of our high-quality medical grade cannabis into the maritime provinces and Quebec, as we look to meet the commercial demand for PPP001,” said Vic Neufeld, CEO of Aphria Inc. “As a leading Canadian licensed producer, it was important for us to work with an organization that shares our focus on pharmaceutical-grade quality assurance and control. Tetra’s emphasis on developing products driven by patient needs and scientific research and development makes them the perfect partner in this important next step for Aphria.”

Tetra and Aphria have invested in the development of its PPP001 drug and will continue to invest to bring PPP001 to market in both Canada and USA as the first prescription drug using dried cannabis. The corporations have developed a high quality dried cannabis product and would like to make it available to physicians under the current ACMPR program. The quality and clinical research studies completed to date would be integrated into a joint Continuing Medical Education program for physicians and pharmacists. Tetra and Aphria have concluded that there is demand for an evidence-based approach in medical cannabis and the two companies intend on using their pharmaceutical approach to help patients. The venture will also be commercializing devices for the inhalation of medical cannabis.

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

About Aphria:

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements – Tetra Bio-Pharma Inc.

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Forward-looking statements – Aphria Inc.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS – APHRIA: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, expectations related to the completion of this project, its revenue and gross margin expectations, expectations for future growing capacity and costs, the completion of any capital project or expansions, any commentary related to the legalization of marijuana and the timing related thereto, expectations of Health Canada approvals and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(343) 689-0714

Aphria Inc.
Nina Godard
Edelman
nina.godard@edelman.com
416-455-6324

Aphria Inc.
Vic Neufeld
President & CEO
1-844-427-4742

The marijuana market could be (and possibly already is) bigger than the market for beer in Canada $TBP.ca $N.ca

Posted by AGORACOM-JC at 5:20 PM on Thursday, April 13th, 2017

The marijuana market could be (and possibly already is) bigger than the market for beer in Canada

Pot’s retail therapy

TORONTO — It’s a hot, sunny Thursday afternoon on the hard edge of Queen Street West, and the foot traffic at Eden, a pot dispensary, is brisk.

Retailers along this strip of trendy clothing stores, bars, restaurants, shoe shops, tattoo parlours, hairstylists, comic stores and coffee joints cater to the urban hip, and Eden is no different. lnside, iceberg-blue lights illuminate jewel-case cabinets with the product — glass vials of Hindu Kush, El Hefe, Organic Blue Dream — artfully displayed.

On the aquamarine-blue wall at the front are two white iPads, for customers who need quick access to the Internet to check product information.

The place is spotless, sharp. And the air is heavy with the unmistakeable sweet smell of cannabis.

Pot store
The fridge at Eden Medicinal Society, a cannabis retailer in Toronto. (Tyler Anderson / National Post)

Behind the counter, two clerks, a man and a woman both in their 20s, both dressed like their customers, are filling orders, taking cash.

The average transaction, those in the business say, is $50. A pre-rolled joint is $12, but Alicia, the manager, says they won’t start selling a lot of those until the evening, when the university crowd and the kids from the suburbs come downtown.

The afternoonwalk-ins are largely cannabis users who rely on the flowers, ointments, teas, and oils to ease some chronic ailment, or they are creative types — writers, graphics artists, filmmakers — who find extra insight and energy through cannabinoid stimulation. They all have prescriptions from a licensed physician.

The product mix and retail approach at Eden’s downtown store is different than what you will find at the company’s newest outlet a few blocks north near Bayview and Eglinton. There are more seniors and aging baby boomers in that neighbourhood so the store opens earlier and closes earlier.

The Eden outlets are among the 100 or so pot dispensaries in Toronto, but there is easily demand, those in the industry say, for 1,000 such businesses.

They are owned and operated by a mix of campaigners and capitalists.


The campaigners have been working for years to legalize marijuana use. They believe in the huge potential for the drug to manage pain, ease anxiety, and help many to a more productive, happy, creative and healthy existence.

Tania Cyalume and Brandy Zurborg opened their storefront dispensary, Queens of Cannabis, on Bloor Street West just north of Little Italy in February.

Queens of Cannabis owners Tania Cyalume and Brandy Zurborg outside their shop in May 2016. (Maryam Shah / Postmedia Network)

“I guess when you believe in a product, you really believe in it because you’ve seen the way that it affects people,” said Cyalume.

The products Cyalume and Zurborg sell and their approach to retailing match their personal philosophies and lifestyles. Both are vegans, and the edible cannabis products they stock are vegan and  pesticide-free.

Their crusade is about serving patients because they are patients themselves, and use cannabis products regularly to treat their own chronic pain and ailments.

“We’re patients and we believe in it. We also believe that patients have the first right to access before recreational. There is only so much supply, and there is a huge demand,” said Zurborg, who trained as a certified management accountant designation and was  an auditor with the Canada Revenue Agency.

Their goal is not necessarily to get rich. They speak of one day being able to use the proceeds of their retail operation to help fund outreach, at hospices for example, where they can spread the word about the life-changing value of cannabis products.

Marina, who preferred her last name not be used, is a capitalist. She and her husband have had as many as seven dispensaries, some through a franchise model they were trying to build. When she got into the business a few years ago, she approached with a capitalist’s zeal and eye for profit.

The woman has agreed to talk about her industry at an upscale diner set among the forest of steel-and-glass condominium towers where Lake Ontario meets the Toronto suburb of Etobicoke. She arrived in a gleaming white SUV. Petite, direct and energetic, Marina makes no bones about the fact she got into the business to make a pile of cash.

- See more at: http://news.nationalpost.com/features/o-cannabis-retail-therapy#sthash.q9qC3FZy.dpuf

Tetra Bio-Pharma Announces Opening of a New Brunswick Office for Manufacturing & Sales Activities $TBP.ca

Posted by AGORACOM-JC at 4:46 PM on Wednesday, April 12th, 2017

Tbp large

  • Announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities
  • New Brunswick becoming the hub for the Canadian Cannabis industry

OTTAWA, ONTARIO–(April 12, 2017) - Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities. New Brunswick is becoming the hub for the Canadian Cannabis industry.

Tetra is preparing to commercialize several retail products later this year with expected revenues to be generated for the corporation in the fourth quarter. Tetra has already initiated the process to manufacture the first products that act on the cannabinoid system that will be commercialized later this year for sale in Canada and the USA. The Company also intends on commercializing devices (e.g., pipes) for the consumption of medical marijuana in 2017. The Tetra office in Moncton will be responsible to oversee the timely production and launch of the products as well as adhering to the corporation’s budgets.

Tetra has initiated its Phase I clinical trial in March 2017 after manufacturing the PPP001 cannabis drug product at the Ford Pharma contract manufacturing facility in Moncton, New Brunswick. This contract facility developed the proprietary process and equipment required to produce PPP001 pellets and packaging operations. Tetra is also using the contract services of RPC, a New Brunswick provincial crown corporation, to perform its quality control studies to assure that PPP001 conforms to its drug product specifications and quality requirements of a prescription drug.

“We are pleased to announce the opening of a new office in New Brunswick which has become one of the leading provinces in Canada to support the cannabis industry,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra will manufacture our PPP001 prescription drug as well as additional scheduled products later this year. We are advancing our projects forward which are on time and on budget, a key priority for the Tetra team. We are now one-step closer towards our goal of commercialization in bringing our innovative cannabis based products to market.”

“We acted quickly to prepare for the development of this industry in New Brunswick,” said Stephen Lund, CEO of Opportunities NB. “The addition of Tetra Bio-Pharma to the province is welcomed news. We have the research, education and production facilities in place for companies to be successful in this rapidly growing industry.”

According to Dr. Guy Chamberland, CSO at Tetra Bio-Pharma Inc., “The use of the facility in Moncton allows Tetra to manufacture the PPP001 drug product for the clinical trial according to the corporation’s timelines and budget. The RPC research and technology organization provides Tetra with the high-level expertise required for assessing the quality aspects of PPP001 while keeping the costs associated with these activities within budget due to RPC not-for-profit status. I can report that the Phase 1 trial is advancing on schedule and according to the corporation’s plans we expect to complete the Phase Ia portion of the study by mid-May. The results of the Phase Ia will provide TBP with a strategic understanding of the commercial potential of marijuana products and allow the corporation to complete its Phase II and III trial plans.”

About Tetra Bio Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQX:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(343) 689-0714

Tetra Bio-Pharma Upgrades to OTCQB to Engage and Expand U.S. Investor Audience $TBP.ca

Posted by AGORACOM-JC at 4:44 PM on Wednesday, April 5th, 2017

Tbp large

  • Announced that effective tomorrow, shares of the Company have been approved for and will commence trading on the OTCQB venture marketplace
  • Ticker symbol GRPOF

OTTAWA, ONTARIO–(April 5, 2017) - Tetra Bio-Pharma Inc. (“Tetra“) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF), today announced that effective tomorrow, shares of the Company have been approved for and will commence trading on the OTCQB venture marketplace, operated by OTC Markets Group, under the ticker symbol GRPOF. Shares of the Company previously traded on the OTCQI Pink Sheet Market. The Company also reiterated its strategy to create greater opportunity for its shareholders and attract new U.S. retail and institutional investors by providing transparency via this up-listing.

“We are extremely pleased to announce our up-list to the OTCQB Venture Marketplace,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra is committed to the high level of financial and corporate disclosure that is required for this listing category which further demonstrates significant improvement in how we are categorized in the public markets. This move represents our expansion in growing our U.S. investor shareholder base as we believe that trading on the OTCQB will enhance trading liquidity and continue to increase market adoption of our business model, thereby enhancing shareholder value. We look forward to aggressively executing our business plan as we build a leading bio-pharmaceutical organization focused on developing medicinal cannabis as pharmaceutical drugs.”

The OTCQB is considered by the SEC as an established public market for the purpose of determining the public market price when registering securities for resale with the SEC. The OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements, the majority of broker dealers trade stocks on the OTCQB. Historically this has resulted in greater liquidity and awareness for companies that reach the OTCQB tier.

McMillan LLP serves as Tetra’s OTCQB advisor, responsible for providing professional guidance on OTCQB requirements and U.S. securities laws. U.S. investors can find current financial disclosure and quotes for the company on www.otcmarkets.com.

About Tetra Bio Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQX:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(343) 689-0714
edward@tetrabiopharma.com
www.tetrabiopharma.com

Health Canada urged to clear the way for medical pot insurance $TBP.ca

Posted by AGORACOM-JC at 11:07 AM on Wednesday, April 5th, 2017

Medical marijuana advocates in Alberta say Ottawa needs to expedite safety approvals that would allow insurance companies to provide coverage for costly prescriptions.

  • As the federal government prepares to legalize recreational marijuana by July 2018, Grindle is among the advocates calling on Health Canada  to clear the way for coverage of legally-prescribed pot.

Medical marijuana advocates in Alberta say Ottawa needs to expedite safety approvals that would allow insurance companies to provide coverage for costly prescriptions. (CBC)

Related Stories

Conventional pills did little to ease Jill Grindle’s PTSD and sleep disorder, but within months of turning to medical marijuana the Calgary mother says she was sleeping through the night.

Now she has another worry.

“It’s costing a pretty penny,” she said. “So what I do is I under-medicate greatly. I scrimp and I save and I only use it very sparingly.”

Like most Canadians, Grindle’s standard insurance plan doesn’t cover legally prescribed cannabis. For Grindle that adds up to $1,200 a month if she were to use her full four-gram daily allowance, so she gets by on one gram a day.

As the federal government prepares to legalize recreational marijuana by July 2018, Grindle is among the advocates calling on Health Canada  to clear the way for coverage of legally-prescribed pot.

With the exception of limited coverage for veterans and patients with health care spending accounts, the standard insurance of most Canadians doesn’t reimburse the cost of medical cannabis.

Kait Shane, director of community outreach with Calgary-based Natural Health Services, describes it as the “missing link,” noting Canadians can claim cannabis on their their tax returns and travel with it on federal flights.

“Every patient comes in and is kind of wondering the same thing. Can we be covered; will we be covered?” said Shane, whose Calgary-based company prescribes cannabis at several western locations including Edmonton.

She said the problem is that medical marijuana doesn’t have a drug identification number (DIN); a classification that requires going through a rigorous, expensive approval process required of all new drugs.

Kait Shane with Natural Health Services says out-of-reach cannabis prices push some patients to illegal sources.

“It’s a matter of lobbying … to get Health Canada to recognize it’s not feasible for them to go through the same trials as other drugs,” said Shane, who points out that unlike other narcotics, cannabis has been used for a long time.

Shane worries not insuring medical cannabis will alienate those who can’t afford to get it through licensed producers.

“High costs currently push many patients to seek alternative options through illegal avenues with zero testing protocols,” she said. “The lack of testing could put a patient’s health at risk.”

Joan Weir, director of health police at the Canadian Life and Health Insurance Association, said the process is moving slowly, despite some employers adding coverage.

“There’s not a lot of good research on the impact of adding medical marijuana to your drug program,” said Weir. “So there needs to be a fair bit more research to make employers comfortable on including it as a benefit.”

Health Canada wasn’t immediately available for comment.

Source: http://www.cbc.ca/news/canada/edmonton/health-canada-urged-to-clear-way-for-medical-pot-insurance-1.4053888

Tetra Bio-Pharma and IntelGenx Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet $TBP.ca

Posted by AGORACOM-JC at 8:45 AM on Monday, April 3rd, 2017

Tbp large

  • Signed definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol
  • for the management of anorexia and cancer chemotherapy-related pain
  • U.S. cancer pain market is expected to reach $5 billion in 2018

OTTAWA, ONTARIO–(April 3, 2017) - Tetra Bio-Pharma Inc. (“Tetra“) (CSE:TBP)(OTC PINK:GRPOF) and IntelGenx Corp. (“IntelGenx”) (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the signing of a definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol (the “Product”) for the management of anorexia and cancer chemotherapy-related pain. The U.S. cancer pain market is expected to reach $5 billion in 2018. This definitive agreement follows the binding term sheet between the two companies that was announced on February 9, 2017.

Pursuant to the definitive agreement, Tetra has exclusive rights to sell the Product in North America, with a right of first negotiation for territories outside of the United States and Canada. Tetra will make an upfront payment to IntelGenx, in addition to set future milestone and royalty payments, based on the completion of an efficacy study, approvals from the U.S. Food and Drug Association (“FDA”) and Health Canada, and the commercial launch of the Product. IntelGenx will be responsible for the research and development of the Product, including clinical studies, and will develop the product as an oral mucoadhesive tablet based on its proprietary AdVersa® controlled-release technology. Tetra will be responsible for funding the product development, and will own and control all regulatory approvals, including the related applications, and any other marketing authorizations. Tetra will also be responsible for all aspects of commercializing the Product.

“We are pleased to announce the closing of the definitive agreement with IntelGenx and look forward to working very hard with them to bring this much-needed product to patients suffering from cancer pain,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “The execution of this agreement is just the beginning for Tetra as we look forward to aggressively concluding future agreements as we build a leading bio-pharmaceutical organization focused on developing medicinal cannabis as pharmaceutical drugs.”

“The U.S. cancer pain market is expected to reach $5 billion in 2018, and the quick growing medical cannabis industry is poised to capture a signature portion of that opportunity,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “We are pleased to be working with Tetra to bring this much-needed cannabinoid product to North American patients suffering from anorexia and cancer chemotherapy-related pain.”

Background Information: 

There are many clinical problems associated with the use of currently available form of Dronabinol in patients with anorexia and cancer chemotherapy-related pain. It has been demonstrated that psychoactive drugs exert their euphoria, and other psychoactive effects, when the blood levels of the drug rapidly increase. The pharmacokinetic profile of tetrahydrocannabinol (“THC”) and its metabolite increases the abuse potential of cannabinoids like Dronabinol. The significant advantage of an oral mucoadhesive tablet based on IntelGenx’ proprietary AdVersa® controlled-release technology is that it can be adjusted to achieve a predetermined drug release pattern by increasing the residence time, promoting intimate contact with the mucosal tissue and increasing the bioadhesive properties of the dosage form. It is believed that, by deploying this technology in the controlled-release of THC, a longer time release of the drug will be achieved and, thereby, a rapid increase in the blood will be avoided. There will also potentially be improved bioavailability and reduced gastro-intestinal side effects, making a sustained-release THC product a promising alternative in the battle for the reduction of opioids in patients with chronic pain.

About IntelGenx:

IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.

IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.

About Tetra Bio Pharma: 

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP) (OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(343) 689-0714
www.tetrabiopharma.com

Marijuana industry gets boost from anticipated legalization target date $TBP.ca $MCOA.us

Posted by AGORACOM-JC at 9:55 AM on Tuesday, March 28th, 2017

Canadian marijuana businesses got a confidence boost from a CBC News report that the government plans to legalize recreational marijuana by July 2018, although big questions remain about how the legal market will work in different provinces.

The newly revealed date for the debut of legal cannabis is “exactly along the lines of what we expected,” said Neil Maruoka, a stock analyst with Canaccord Genuity who covers publicly traded marijuana companies.

“Certainly there are some companies with more aggressive expansion plans, and this will give some comfort and clarity on what that path forward is going to be,” he said.

Stocks in Canadian marijuana companies swelled on Monday. Shares of Canopy Growth Corp., Canada’s largest publicly traded marijuana producer, gained more than 11 per cent. Shares of Aphria, another large player, gained about 8.4 per cent.

The tabling of the legislation, expected the week of April 10, should be “the tide that lifts all cannabis stocks,” said Maruoka.

Licensed producers bet on recreational sales

Currently, 39 marijuana producers are licensed by Health Canada to cultivate medical marijuana and sell it to patients via a mail-order system. Some of those companies are spending heavily to build up their growing capacity, betting that they’ll be well positioned to sell into the recreational market as soon as the green flag waves.

Alberta-based Aurora Cannabis, which is building an 800,000 square-foot farm near Edmonton International Airport, welcomed the reassurance that Ottawa is committed to recreational sales.

“This is something that we planned on and that’s why we started construction on this enormous facility,” Aurora executive vice-president Cam Battley told CBC Edmonton on Monday.

Canopy Growth CEO Bruce Linton also said the legalization date is in line with his company’s plans.

“It means everything that’s been predicted to be on a path is on a path,” said Linton.

“And when you’re dealing with a government, you can expect things not to stay that course, but they have.”

Who will be allowed to sell?

Even if they weren’t surprised by the date, players in the Canadian marijuana market are taking notice of the news that individual provinces will be deciding how marijuana is sold.

“The dispensary groups, depending on how this plays out, could be big winners,” said Mark Lustig, CEO of CannaRoyalty Corp., which invests in legal aspects of the marijuana industry.

Pharmacies like Shoppers Drug Mart, London Drugs, and Jean Coutu could also benefit if provincial governments tap them as marijuana distributors, said Lustig.

CANADA MARIJUANA/REGULATIONS

Marijuana dispensaries, currently illegal under federal law, could benefit if individual provinces let them sell legal marijuana. (Julie Gordon/Reuters)

In Ontario, the union that represents Liquor Control Board of Ontario workers has pushed for marijuana sales through the government liquor monopoly.

Ontario Premier Kathleen Wynne said Monday that the provincial government has not yet decided who will get to sell marijuana in Canada’s most populous province, although she previously said “it makes sense” to sell marijuana through the LCBO.

Colette Rivet of the Cannabis Canada Association, which represents 15 licensed producers, says her organization’s members favour leaving the mail-order system for medical marijuana in place, and potentially expanding it to recreational sales.

Still, Rivet acknowledges that brick-and-mortar retail sales are “likely to happen, of course.”

In its submission to the federal task force on marijuana legalization, Cannabis Canada said it was against selling alcohol and marijuana in the same location.

Dispensaries hope for inclusion

Owners of some marijuana dispensaries, which are illegal under federal law, are also hoping the provinces will cut them in on the legal marijuana market.

“We feel that we have a very good potential to be included in a regulated environment,” said Jeremy Jacob, a Vancouver dispensary owner and president of the Canadian Association of Medical Cannabis Dispensaries.

In many Canadian cities, dispensaries are frequently raided and shut down by police. But Jacob points out that some B.C. dispensaries have good relationships with local governments in Vancouver and Victoria, where marijuana shops can be licensed by municipal authorities.

Jacob expressed hope that those existing government ties could help pave the way for dispensaries — and the unlicensed producers who grow their product — to take part in the legal marijuana economy in B.C.

“We’re waiting to see how inclusive they actually are,” said Jacob.

Source: http://www.cbc.ca/news/business/marijuana-businesses-legalization-date-1.4042599